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This is the final issue of CDC (Seasonal) Influenza Division Key Points for the 2016-2017 
influenza season. After today, seasonal influenza key points will no longer be released on 
a fixed schedule, but will be issued as they are warranted, such as in conjunction with the 
release of important flu-related publications or guidance or unexpected increases in flu 
activity. Full reporting for the 2017-2018 influenza season will begin in mid-October 2017, 
and appear in the weekly influenza surveillance report, FluView. 
 
In this document: 
 Summary Key Points 
 FluView Activity Update 
 Influenza-Associated Pediatric Deaths 
 Antiviral Drug-Resistant Influenza Virus 
 
Summary Key Points 
 Flu activity continues to decrease in the United States according to the most recent 
FluView report. (http://www.cdc.gov/flu/weekly) 
 Influenza-like illness is below baseline. 
 Flu activity has peaked and activity is winding down for this season in most of the 
country. 
 Only one state is still reporting widespread flu activity. 
 Influenza B viruses have been most common in the last few weeks; however 
overall, H1N1 viruses have been predominant this season. 
 Second waves of influenza B activity occur during many flu seasons. 
 The peak week of flu activity for the 2015-2016 season was week 10; the week 
ending March 12, 2016. 
 This is a relatively late peak for a flu season. 
 There is still some circulation of flu, and it's important to note that flu viruses 
circulate at low levels, even over the summer. CDC recommends influenza 
vaccination as long as influenza viruses are circulating and vaccine is available.  
 CDC also recommends that patients suspected of having influenza who are at high-
risk or who are very sick (http://www.cdc.gov/flu/about/disease/high_risk.htm) 
should receive prompt treatment with influenza antiviral drugs without waiting for 
confirmatory testing. 
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 More information about flu antiviral medications is available at: 
http://www.cdc.gov/flu/antivirals/index.htm  
 CDC posted a web spotlight for a collaborative study on Improved Global Capacity 
for Influenza Surveillance: http://www.cdc.gov/flu/news/collaborative-study-
capacity.htm. The manuscript is available online in Emerging Infectious Diseases: 
http://wwwnc.cdc.gov/eid/article/22/6/15-1521_article.    
 
  
FluView Activity Update 
According to this week’s FluView report, flu activity continues to decrease in the United 
States. Flu activity has peaked nationally for this season and is winding down. Only Puerto 
Rico and one state reported widespread flu activity. Influenza B viruses have been most 
common in recent weeks; however, H1N1 viruses have been predominant overall this 
season. Second waves of influenza B activity occur during many flu seasons. CDC 
continues to recommend influenza vaccination as long as influenza viruses are circulating. 
CDC also recommends that patients suspected of having influenza who are at high risk of 
flu complications or who are very sick with flu-like symptoms should receive prompt 
treatment with influenza antiviral drugs without waiting for confirmatory testing. Below is 
a summary of the key flu indicators for the week ending May 21, 2016: 
 For the week ending May 21, the proportion of people seeing their health care 
provider for influenza-like illness (ILI) decreased to 1.3%. This is below the national 
baseline of 2.1%. All 10 regions reported ILI below their region-specific baseline 
levels. One way that CDC measures the duration of the influenza season is the 
number of consecutive weeks during which ILI is at or above the national baseline. 
ILI was at or above the national baseline for 17 consecutive weeks this season. For 
the last 13 seasons, the average duration of a flu season by this measure has been 
13 weeks, with a range from one week to 20 weeks. 
 Puerto Rico experienced moderate ILI activity. Three states (Arizona, Georgia, and 
North Carolina) experienced low ILI activity. New York City and 46 states 
experienced minimal ILI activity. The District of Columbia and one state (New 
Jersey) did not have sufficient data to calculate an activity level. ILI activity data 
indicate the amount of flu-like illness that is occurring in each state. 
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 Widespread flu activity was reported by Puerto Rico and one state (New York). This 
is a decrease from two states with widespread activity last week. Regional flu 
activity was reported by Guam and six states (Connecticut, Kentucky, Maine, 
Massachusetts, New Hampshire, and Pennsylvania). Local flu activity was reported 
by 14 states (Alabama, Alaska, Arizona, Delaware, Hawaii, Michigan, New Jersey, 
New Mexico, Ohio, Oklahoma, South Carolina, Vermont, West Virginia, and 
Wisconsin). Sporadic flu activity was reported by the District of Columbia, the U.S. 
Virgin Islands, and 28 states (Arkansas, California, Colorado, Florida, Georgia, 
Idaho, Illinois, Iowa, Kansas, Louisiana, Maryland, Minnesota, Mississippi, Missouri, 
Montana, Nebraska, Nevada, North Carolina, North Dakota, Oregon, Rhode Island, 
South Dakota, Tennessee, Texas, Utah, Virginia, Washington, and Wyoming). No 
activity was reported by one state (Indiana).  Geographic spread data show how 
many areas within a state or territory are seeing flu activity. 
 Between October 1, 2015, and April 30, 2016, 8,646 laboratory-confirmed 
influenza-associated hospitalizations have been reported through FluSurv-NET, a 
population-based surveillance network for laboratory-confirmed influenza-
associated hospitalizations. This translates to a cumulative overall rate of 31.2 
hospitalizations per 100,000 people in the United States. This is significantly lower 
than the hospitalization rate at this time last season (64.1 per 100,000), which was 
an H3N2 predominant season. During the last H1N1 predominant season (2013-
2014), the cumulative hospitalization rate was 35.1. More data on hospitalization 
rates, including hospitalization rates during other influenza seasons, are available 
at http://gis.cdc.gov/GRASP/Fluview/FluHospRates.html and 
http://gis.cdc.gov/grasp/fluview/FluHospChars.html.  
o The highest hospitalization rates are among people 65 years and older (84.2 
per 100,000), followed by adults 50-64 years (45.1 per 100,000) and 
children younger than 5 years (42.0 per 100,000). During most seasons, 
adults 65 years and older and children younger than 5 years have the 
highest hospitalization rates. 
o FluSurv-NET hospitalization data are collected from 13 states and represent 
approximately 8.5% of the total U.S. population. The number of 
hospitalizations reported does not reflect the actual total number of 
influenza-associated hospitalizations in the United States. 
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 The proportion of deaths(http://www.cdc.gov/flu/weekly/#S2) attributed to 
pneumonia and influenza (P&I) was below the system-specific epidemic threshold in 
both the NCHS Mortality Surveillance System and the system-specific epidemic 
threshold in the 122 Cities Mortality Reporting System. 
 Two additional influenza-associated pediatric deaths 
(http://www.cdc.gov/flu/weekly/#S3) were reported to CDC this week:  
o One death was associated with an influenza A (H1N1)pdm09 virus and 
occurred during week 8 (the week ending February 27, 2016).  
o One death was associated with an influenza A virus for which no subtyping 
was performed and occurred during week 19 (the week ending May 14, 
2016).  
o This brings the total number of flu-associated pediatric deaths reported this 
season to 70 children. 
 Nationally, the percentage of respiratory specimens testing positive for influenza 
viruses in clinical laboratories during the week ending May 21 was 6.3%. For the 
most recent three weeks, the regional percentage of respiratory specimens testing 
positive for influenza viruses in clinical laboratories ranged from 2.7% to 11.0%. 
o During the week ending May 21, of the 628 influenza-positive tests reported 
to CDC by clinical laboratories, 198 (31.5%) were influenza A viruses and 
430 (68.5%) were influenza B viruses. 
 The most frequently identified influenza virus type reported by public health 
laboratories during the week ending May 21 was influenza A viruses. 
o During the week ending May 21, 35 (50.7%) of the 69 influenza-positive 
tests reported to CDC by public health laboratories were influenza A viruses 
and 34 (49.3%) were influenza B viruses. Of the 35 influenza A viruses that 
were subtyped, 19 (54.3%) were H3 viruses and 16 (45.7%) were 
(H1N1)pdm09 viruses.  
 Cumulatively from October 4, 2015-May 21, 2016, influenza A (H1N1)pdm09 
viruses were predominant in all four age groups: 0-4 years age group (69.9%), 5-
24 years age group (48.1%),  25-64 years age group (68.4%), and in ages 65 
years and older (50.3%).  
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 CDC has characterized 2,514 specimens (931 influenza A (H1N1)pdm09, 590 
influenza A (H3N2) and 993 influenza B viruses) collected in the United States since 
October 1, 2015.  
o 930 of 931 (99.9%) influenza A (H1N1)pdm09 viruses were antigenically 
characterized as similar to A/California/7/2009, the influenza A (H1N1) 
component of the 2015-2016 Northern Hemisphere vaccine. 
o All 590 H3N2 viruses were genetically sequenced and all viruses belonged to 
genetic groups for which a majority of viruses antigenically characterized 
were similar to cell-propagated A/Switzerland/9715293/2013, the influenza A 
(H3N2) component of the 2015-2016 Northern Hemisphere vaccine.  
o A subset of 285 H3N2 viruses also were antigenically characterized; 277 of 
285 (97.2%) H3N2 viruses were similar to A/Switzerland/9715293/2013 by 
HI testing or neutralization testing. 
o All 548 (100%) of the B/Yamagata-lineage viruses were antigenically 
characterized as similar to B/Phuket/3073/2013, which is included in both 
the 2015–2016 Northern Hemisphere trivalent and quadrivalent vaccines. 
o 438 of 445 (98.4%) of the B/Victoria-lineage viruses were antigenically 
characterized as similar to B/Brisbane/60/2008, which is included in the 
2015-2016 Northern Hemisphere quadrivalent vaccine. 
 Since October 1, 2015, CDC has tested 2,090 influenza A (H1N1)pdm09, 699 
influenza A (H3N2), and 1,104 influenza B viruses for resistance to the 
neuraminidase inhibitors antiviral drugs. While the vast majority of the viruses that 
have been tested are sensitive to oseltamivir, zanamivir, and peramivir, so far this 
season, 18 (0.9%) influenza A (H1N1)pdm09 viruses have showed resistance to 
oseltamivir and peramivir. 
 The Food and Drug Administration’s Vaccines and Related Biological Products 
Advisory Committee (VRBPAC) endorsed the WHO-recommended vaccine viruses 
for use in all U.S. seasonal flu vaccines for the 2016-2017 flu season.  These 
recommendations were as follows:  
o It was recommended that trivalent vaccines for use in the 2016-2017 
influenza season (Northern Hemisphere winter) contain the following:  
 an A/California/7/2009 (H1N1)pdm09-like virus; 
 an A/Hong Kong/4801/2014 (H3N2)-like virus; 
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 a B/Brisbane/60/2008-like virus (B/Victoria lineage). 
o It was recommended that quadrivalent vaccines containing two influenza B 
viruses contain the above three viruses and a B/Phuket/3073/2013-like virus 
(B/Yamagata lineage). 
o This represents a change in the influenza A (H3) component and a change in 
the influenza B lineage included in the trivalent vaccine compared with the 
composition of the 2015-2016 influenza vaccine. 
 
FluView (http://www.cdc.gov/flu/weekly/fluactivitysurv.htm) is available – and past issues 
are archived (http://www.cdc.gov/flu/weekly/pastreports.htm) – on the CDC website. 
Note: Delays in reporting may mean that data changes over time. The most up to date 




Influenza-Associated Pediatric Deaths 
 Two pediatric deaths were reported this week, bringing the total number of flu-
associated deaths to 70 for the 2015-2016 season.  
 Because of confidentiality issues, CDC does not discuss or give details on individual 
cases.  
 These deaths are a somber reminder of the danger flu poses to children.  
 The single best way to protect against seasonal flu and its potential severe 
consequences in children is to get a seasonal flu vaccine each year.  
 Vaccination is especially important for children younger than 5 years of age and 
children of any age with a long-term health condition like asthma, diabetes and 
heart disease and neurological and neurodevelopmental diseases. These children 
are at higher risk of serious flu complications if they get the flu. 
 Yearly vaccination also is especially important for people in contact with high risk 
children in order to protect the child (or children) in their lives from the flu.  In 
particular, children younger than 6 months are too young to be vaccinated 
themselves but are at high risk of flu complications if they get sick so the people 
around them should get vaccinated to protect the infant. 
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 Some children 6 months through 8 years of age require two doses of influenza 
vaccine. Children in this age group who are getting vaccinated for the first time will 
need two doses. Some children who have received influenza vaccine previously also 
will need two doses this season. A health care provider should be consulted to 
determine whether two doses are recommended for a child. 
 Flu-related deaths in children younger than 18 years old should be reported 
through the Influenza-Associated Pediatric Mortality Surveillance System. The 
number of flu-associated deaths among children reported during the 2015-2016 flu 
season will be updated each week and can be found at 
http://www.cdc.gov/flu/weekly/ and 
http://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html.  
 Since 2004, when pediatric deaths associated with influenza infection became a 
nationally notifiable condition, the number of deaths reported to CDC each year has 
ranged from 37 (2011-2012 season) to 171 deaths (2012-2013 season).  
 Last season, 148 influenza-associated pediatric deaths were reported to CDC.  
 
 
Antiviral Drug-Resistant Influenza Virus 
 Influenza viruses can sometimes develop resistance to antiviral medications. 
 Antiviral resistance means that a virus has changed in such a way that the antiviral 
drug is less effective in treating or preventing illnesses caused by the virus.  
 Influenza viruses constantly change as the virus makes copies of itself. Some 
changes can result in the viruses being resistant to one or more of the antiviral 
drugs that are used to treat or prevent influenza.  
 Resistance of influenza A viruses to antiviral drugs can occur spontaneously or 
emerge during the course of antiviral treatment. 
 Antiviral resistance is detected through laboratory testing. 
 CDC reports specimens collected and tested through national surveillance as well as 
additional specimens tested at public health laboratories who share testing results 
with CDC.  
 For the week ending May 14, 2016 (week 19), one additional resistant influenza 
A(H1N1)pdm09 virus was reported, bringing the total number of antiviral drug-
resistant viruses to fifteen (0.7%) for this season.  
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 CDC tested the virus and confirmed resistance to oseltamivir and peramivir, two 
neuraminidase inhibitor antiviral medications. 
 Oseltamivir resistance and peramivir resistance are rare among influenza A 
(H1N1)pdm09 viruses. 
 The majority of influenza A (H1N1)pdm09 viruses circulating in the United States 
remain susceptible to currently recommended neuraminidase inhibitor antiviral 
medications (oseltamivir, peramivir, and zanamivir). 
 This virus has a single known mutation in the neuraminidase protein (referred to as 
‘H275Y’) that is associated with resistance to neuraminidase inhibitor antiviral 
medications.  
 This is a known mutation in H1N1 viruses, first detected in 2008, and continues to 
be rarely observed among H1N1pdm09 viruses.  
 During the 2013-2014 and 2014-2015 seasons, of the influenza A (H1N1)pdm09 
viruses that were tested for resistance to influenza antiviral drugs, <2% were 
resistant.  All the resistant viruses have had the H275Y mutation. 
 CDC and state and local partners will continue to watch influenza viruses closely for 
possible emerging patterns of antiviral resistance in addition to watching for 
antigenic and genetic changes. 
 Three FDA-approved influenza antiviral medications are recommended for use in 
the United States during the 2015-2016 influenza season: oseltamivir (Tamiflu®), 
peramivir (Rapivab®), and zanamivir (Relenza®). More information about antiviral 
drug resistance can be found at 
http://www.cdc.gov/flu/about/qa/antiviralresistance.htm and 
http://www.cdc.gov/flu/antivirals/index.htm.  
 Information on monitoring for antiviral drug-resistant influenza viruses is updated 
weekly in the CDC FluView surveillance report, which is available at: 
http://www.cdc.gov/flu/weekly/. 
 
 
